Literature DB >> 6330293

Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Y F Liaw, C M Chu, D Y Lin, I S Sheen, C Y Yang, M J Huang.   

Abstract

The age-specific prevalence of hepatitis B e antigen (HBeAg) and its antibody (anti-HBe) were studied by radioimmunoassay, and compared in a large series of patients with chronic hepatitis B virus (HBV) infection, including 268 asymptomatic carriers, 389 chronic hepatitis, 114 liver cirrhosis, and 278 hepatocellular carcinoma (HCC). The prevalence of HBeAg/anti-HBe in asymptomatic carriers and patients with chronic hepatitis correlated closely with age as HBeAg prevalence decreased and anti-HBe prevalence increased with increasing age (P less than 0.0005), and is probably due to high infection rate at young age in Taiwan. The prevalence of HBeAg in patients with both cirrhosis and HCC are much significantly lower and had no correlation with age. Two peaks of age-specific prevalence of HBeAg and anti-HBe were observed in patients with HCC, implicating two patterns of HBV infection in these patients. The difference in the prevalence of HBeAg and anti-HBe might indicate that asymptomatic carriers, chronic hepatitis, liver cirrhosis, and HCC are sequential sequelae of HBV infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330293     DOI: 10.1002/jmv.1890130410

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Icteric flare of chronic hepatitis B in a 95-year old patient.

Authors:  W Song; Wai Keung Leung; Henry L Y Chan
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

2.  Induction of apoptosis in a human hepatocellular carcinoma cell line by a neutralizing antibody to transforming growth factor-alpha.

Authors:  S Seki; Y Sakai; T Kitada; N Kawakita; A Yanai; H Tsutsui; H Sakaguchi; T Kuroki; T Monna
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

3.  Prevalence of HBeAg, anti-HBe serological markers and HBV-DNA in asymptomatic carriers in Ethiopia.

Authors:  M Rapicetta; K Hailù; G Morace; L Bisanti; A M Di Rienzo; A R Ciccaglione; D Bekura; P Pasquini; G B Rossi
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

4.  Natural history and prognostic factors for chronic hepatitis type B.

Authors:  G Fattovich; L Brollo; G Giustina; F Noventa; P Pontisso; A Alberti; G Realdi; A Ruol
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

5.  Chronic hepatitis B in Asian women of childbearing age.

Authors:  Nancy Leung
Journal:  Hepatol Int       Date:  2009-07-09       Impact factor: 6.047

Review 6.  Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.

Authors:  Ceen-Ming Tang; Tung On Yau; Jun Yu
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma.

Authors:  Li-Shuai Qu; Guo-Xiong Zhou
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.

Authors:  Parham Safaie; Mugilan Poongkunran; Ping-Ping Kuang; Asad Javaid; Carl Jacobs; Rebecca Pohlmann; Imad Nasser; Daryl T Y Lau
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 9.  Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.

Authors:  Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

10.  Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

Authors:  H L-Y Chan; A Y Hui; M L Wong; A M-L Tse; L C-T Hung; V W-S Wong; J J-Y Sung
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.